The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000738325
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
27/05/2026
Date registered
Help: Date registered
19/06/2026
Date last updated
Help: Date last updated
2/09/2026
Date data sharing statement initially provided
Help: Data sharing statement date
19/06/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Randomised, double-blind, sham-controlled study of low-intensity focused ultrasound (LIFU) neuromodulation treatment of the Behavioural and Psychological Symptoms of Dementia (BPSD) associated with Alzheimer’s Disease (AD) in adult patients.
Scientific title
Low-intensity focused ultrasound (LIFU) treatment of Behavioural and Psychological Symptoms of Dementia (BPSD) associated with AD in adult patients aged 50 and over.
Additional trial identifiers [1] 317364 0
CERE -CALM
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Alzheimers disease with associated BPSD 342021 0
Condition category
Condition code
Neurological 338103 338103 0 0
Alzheimer's disease

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Neuromodulation using the Ceretas device (second-generation) delivering precise non-invasive low-intensity focused ultrasound (LIFU).
The derated spatial-peak pulse-average (ISPPA) intensity of the pulses is less than or equal to 18.3 W/cm2 in the brain tissue; generated by a defined ultrasound waveform of 10 Hz administered to the region of interest, each pulse is approximately 6 s.
The treatment duration is 30 - 60 minutes per treatment session.
For the first 4 weeks the treatment is applied weekly and then the last 2 treatments monthly.
To monitor adherence to the intervention a caregiver is provided the treatment schedule.
The intervention will be administered in a clinical setting by a trained technician, under the direct supervision of the Principal Investigator who will both be extensively trained in the protocol. A checklist and questions will be completed in each treatment session to ensure compliance with the required steps, and targeted treatment locations will be saved in the IGN software. Sessions of treatment with LIFU last approximately 30-60 minutes in total including setting up navigation, preparing the patient and administering LIFU. LIFU will be delivered to the bilateral precuneus and temporo-parietal association cortex via application of the transducer to the patient’s head and the administration of sonication to the brain region. These participants will receive 100 ultrasound pulses of 10 Hz administered to the region of interest, each pulse is approximately 6 s.
A total of 6 treatments is planned over a 12 week period.
The planned sample size is 66 (2:1 ratio) with a minimum sample size of 60 with participants randomised in a ratio of 2 : 1 (active treatment : sham control) with stratification by baseline symptom score (Neuropsychiatric Inventory (NPI) total score is equal or greater than 12). The 2 : 1 allocation ratio was chosen to support recruitment.
Intervention code [1] 334154 0
Treatment: Devices
Description of the comparator or control
The intervention will be administered in a clinical setting by a trained technician, under the direct supervision of the Principal Investigator who will both be extensively trained in the protocol. A checklist and questions will be completed in each treatment session to ensure compliance with the required steps, and targeted treatment locations will be saved in the IGN software. Sessions of treatment with LIFU last approximately 30 minutes in total including setting up navigation, preparing the patient and administering LIFU. LIFU will be delivered to the bilateral precuneus and temporo-parietal association cortex via application of the transducer to the patient’s head and the administration of sonication to the brain region.
The placebo treatment will differ from the active treatment as the transducer will be applied however no energy will be outputted.
Control group
Placebo

Outcomes
Primary outcome [1] 345500 0
To evaluate the efficacy of the Ceretas device compared with sham on overall neuropsychiatric symptom burden in probable AD.
Timepoint [1] 345500 0
Baseline to week 6 post -baseline.
Secondary outcome [1] 461921 0
To determine if there is any benefit of treatment to caregiver distress as measured by the NPI caregiver distress (NPI-D) scale from baseline to week 6 and week 12 post baseline
Timepoint [1] 461921 0
Baseline to week 6 and week 12 post baseline
Secondary outcome [2] 461922 0
To determine the durability of treatments as measured by the Neuropsychiatric Inventory (NPI; 12 item scale) change from baseline to week 12.
Timepoint [2] 461922 0
Baseline to week 12 post baseline
Secondary outcome [3] 461928 0
To evaluate the overall safety and tolerability of repeated LIFU sessions on participants in the study.
Timepoint [3] 461928 0
From baseline to week 12. post baseline.

Eligibility
Key inclusion criteria
All of the following inclusion criteria must be met for enrolment:
1. Mini-Mental State (MMSE) 10-25.
2. Age 50 years or older.
3. An outpatient living at home or in an assisted living facility, has a knowledgeable informant and is ambulatory.
4. Has a live-in caregiver/informant or, if in assisted living, has a caregiver/informant who spends at least 10 hours per week (spread over at least 5 days/week) in direct contact with the participant and can maintain this through the course of the study. Caregiver/informant must also be able to attend study visits and the same caregiver/informant for all NPI and CMAI (Cohen Mansfield Agitation Inventory) visits.
5. Probable Alzheimer’s disease diagnosis obtained from a clinician according to the criteria of the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA).
6. Clinically significant symptoms present that cause clinically meaningful distress/impairment and are judged to warrant a treatment trial as assessed by Neuropsychiatric Inventory: NPI-12 total score equal or greater than 12 at screening and equal or greater than 12 at Baseline and 1 core domain Frequency and Severity (FxS) equal or greater than 4 at Baseline.
7. The investigator considers the individual medically stable, although BPSD symptoms are present.
8. Individuals who are currently prescribed anti-dementia medications or other psychoactive agents will be eligible for inclusion only if they have been on a stable dose of each medication for a minimum of eight weeks prior to enrolment.
9. Participant’s person responsible must be able to freely give written informed consent; additionally, if, in the clinical judgment of the Principal Investigator, the participant themselves has the mental capacity to provide consent, they will also provide consent.
10. Ability to comply with study regimen and provide contact phone number.
11. Ability to communicate during procedures.
Minimum age
50 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Exclusion Criteria None of the following exclusion criteria must be met for enrolment:
1. Where the source of BPSD symptoms are considered to relate to an acute medical disorder (e.g. active infection, pain).
2. MRI contraindications:
a. Metallic objects in head, or presence of unknown or MR unsafe devices anywhere in body or,
b. Unable to tolerate MRI scanning (e.g. claustrophobia or known inability to lie sufficiently still from previous MRI scans).
3. Haemorrhages (including microhaemorrhages) on MRI scan (expected to be rare).
4. Any other MRI findings that in the opinion of the clinician may be contributing to the clinical profile, including severe ischemic changes, active or chronic infection/inflammation, tumour/space occupying lesion, meningeal enhancement, intracranial hypotension.
5. Paget’s disease of bone.
6. Clotting/bleeding disorder (including oral anti-coagulants; anti-platelet therapy such as low-dose aspirin permitted).
7. Uncontrolled HbA1c outside local laboratory normal reference ranges at baseline.
8. Scalp or skull abnormalities:
a. Prior neurosurgical intervention of the brain / craniotomy or,
b. Skull area traversed by the sonication pathway is covered by scars, scalp disorders (e.g., eczema), open wounds, or atrophy of the scalp.
9. Other neurological diseases (or history of): severe traumatic brain injury, seizure disorders, stroke, tumours, transient ischemic attack:
a. Clinically significant Cerebral pathology unrelated to Alzheimer’s disease
10. History of major psychiatric disorders (such as schizophrenia or bipolar disorder).
11. History of drug or alcohol abuse.
12. An active inflammatory disease.
13. Recurrent or recent history (within four weeks prior to screening) of a clinically significant bacterial, fungal, or mycobacterial infection.
14. Change of allowed, chronic, concomitant medication within 28 days prior to screening.
15. Pregnancy or breast-feeding.
16. Any other major medical illness that in the opinion of the clinician could interfere with the intended use (e.g. unstable cardiovascular, pulmonary, hepatic or renal disease, active cancer etc.).
17. Any conditions that render the participant unable to lie flat for scanning.
18. Known cerebral or systemic vasculopathy.
19. Corticosteroid treatment within last 6 weeks before first treatment.
20. Increased intracranial pressure.
21. Known skin allergies or sensitivity to silicone, ultrasound gel or depilation cream.
22. Participation in other clinical trials within 90 days from the screening date.
23. An inability to communicate during a treatment procedure.
24. A body weight exceeding 135 kg.
25. Other conditions implying increased risk according to the judgement of the investigator.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Software coded randomisation
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Simple randomisation using a randomisation table created by computer software (i.e. computerised sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Other design features
Phase
Not Applicable
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,TAS,VIC

Funding & Sponsors
Funding source category [1] 321937 0
Commercial sector/Industry
Name [1] 321937 0
Ceretas Ltd
Country [1] 321937 0
Australia
Primary sponsor type
Commercial sector/Industry
Name
Ceretas Ltd
Address
Country
Australia
Secondary sponsor category [1] 324807 0
None
Name [1] 324807 0
Address [1] 324807 0
Country [1] 324807 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 320473 0
Bellberry Human Research Ethics Committee E
Ethics committee address [1] 320473 0
Ethics committee country [1] 320473 0
Australia
Date submitted for ethics approval [1] 320473 0
03/03/2026
Approval date [1] 320473 0
04/05/2026
Ethics approval number [1] 320473 0
2026-03-349

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 150586 0
Dr Bita Rajabipour
Address 150586 0
Cognivus Research Centre Parkway SAN Clinic, Suite 214/172 Fox Valley Rd Wahroonga NSW 2076
Country 150586 0
Australia
Phone 150586 0
+61 296879633
Fax 150586 0
Email 150586 0
Contact person for public queries
Name 150587 0
Wendy Lee
Address 150587 0
Ceretas Ltd Level 4 348 Edward Street Brisbane Queensland 4000
Country 150587 0
Australia
Phone 150587 0
+61735434424
Fax 150587 0
Email 150587 0
Contact person for scientific queries
Name 150588 0
Wendy Lee
Address 150588 0
Ceretas Ltd Level 4 348 Edward Street Brisbane Queensland 4000
Country 150588 0
Australia
Phone 150588 0
+617 35434424
Fax 150588 0
Email 150588 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

TypeCitationLinkEmailOther DetailsAttachment
Ethical approval2026   ApprovalLetter-HREC2026-03-349.pdf


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.